Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study

BACKGROUND: Thrombopoietin-receptor agonists (TPO-RAs) are used to treat immune thrombocytopenia (ITP), a disorder characterized by prolonged low platelet counts (PCs) that pose a risk of serious bleeding episodes. Avatrombopag (AVA) is the most recently approved TPO-RA for the treatment of chronic...

Descripción completa

Detalles Bibliográficos
Autores principales: Oladapo, Abiola, Kolodny, Scott, Vredenburg, Michael, Swallow, Elyse, Goldschmidt, Debbie, Sarathy, Kirthana, Lopez, Priscilla, Maitland, Hillary, Yee, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350755/
https://www.ncbi.nlm.nih.gov/pubmed/37465395
http://dx.doi.org/10.1177/20406207231179856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350755/
https://www.ncbi.nlm.nih.gov/pubmed/37465395
http://dx.doi.org/10.1177/20406207231179856

Ejemplares similares